52 results about "Intercellular Adhesion Molecule-1" patented technology

The present invention relates to pharmaceutical compositions for delivery of drugs intended to reside in the nose, compositions for nasal administration of drugs, e.g., antiviral agents, and particularly antiviral agents comprising the human major rhinovirus receptor, also known as intercellular adhesion molecule-1 (ICAM-1); to methods of making said nasal drug compositions, and to an improved process for the removal of residual solvent from pharmaceutical matrices.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

The invention discloses a preparation method of human cytokine-induced killer cells, comprising the following steps: coating a cell culture flask with a coating buffer containing effective amount of fusion protein and human CD3 monoclonal antibody before culturing precursor cells of human CIK cells, and adding the human CD3 monoclonal antibody in the whole process of inducing and culturing the human CIK cells, wherein the fusion protein is human intercellular adhesion molecule-1 functional domain and human fibronectin functional domain fusion protein, and the concentration of the human CD3 monoclonal antibody in the cell culture solution is lower than the concentration of the human CD3 monoclonal antibody in the coating buffer. According to the invention, ex-vivo expansion efficiency of peripheral blood mononuclear cells and the proportion of CD3/CD56 double positive cells in the CIK cells are significantly raised, the cytotoxicity activity of the CIK cells is enhanced, thus the effect of cellular immunity treatment is raised.

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to modulation cell adhesion molecules are disclosed.

This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (compound 1) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder. The invention also relates to tumor necrosis factor- (TNF-α) and interleukin (IL-1, IL-6, IL-8) inhibitory activity of the said compositions. The invention relates to inhibition of the expression of intercellular adhesion molecule 1 (ICAM-1), vascular-cell adhesion molecule 1 (VCAM-1), and E-Selectin by the said compositions. The said compositions may optionally contain at least one anti-inflammatory agent or can be used in combination with at least one anti-inflammatory agent.

An isolated selected Picornavirus capable of lytically infecting or killing a cell substantially in the absence of intercellular adhesion molecule-1 (ICAM-1).

The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.

This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3- methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1 ,2-b]furan-2-one (7- Hydroxy-4,1 1 (13)-eudesmadien-12,6-olide) (compound 1 ), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl- 3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1 ,2-b]furan-2-one (compound 1 ) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder.; The invention also relates to tumor necrosis factor-a (TNF- a) and interleukin (IL-1 , IL-6, IL-8) inhibitory activity of the said compositions. The invention relates to inhibition of the expression of intercellular adhesion molecule 1 (ICAM-1 ), vascular-cell adhesion molecule 1 (VCAM-1 ), and E-Selectin by the said compositions. The said compositions may optionally contain at least one anti-inflammatory agent or can be used in combination with at least one anti- inflammatory agent.

The invention relates to the field of biotechnology and medical science, in particular to a fusion protein for NKT (natural killer T) cell culture, an encoding gene and an application. The fusion protein is used for preparing NKT cells which are high in proliferating activity and killing activity. The fusion protein ICAM1-FN (intercellular adhesion molecule-1-fibronectin) can effectively stimulate proliferation of lymphocytes in the culture process of the NKT cells, the proportion of CD3/CD56 double-positive cells is improved, so that the in-vitro amplification efficiency of peripheral blood mononuclear cells is twice that of a traditional method, the proportion of CD3/CD56 double-positive cells is 2-10 times that of the traditional method, tumor killing activity of the NKT cells is enhanced, and the tumor killing activity of the prepared method of the NKT cells is improved by 15%-35% as compared with the traditional method.

The present invention relates to gene engineering technology. The I-III functional encoding gene outside intercellular adhesion molecule-1 (ICAM-1) membrane is recombined to expression plasmid pET42a, transferred into prokaryotic expression bacteria, and purified to obtain expression product GST-ICAM-1. The expression product is used as antigen in immunizing rabbit to obtain rabbit anti-human polyclonal antibody. Thus prepared expression product of human I-III functional encoding gene outside ICAM-1 membrane in prokaryotic system is easy to purify, low in cost and high in yield. The human serum sICAM-1 radioimmunoassay technology is developed and used in clinical test and has important significance in diagnosing the treating effect of Graves' disease.

The present invention relates to a method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least one cell surface receptor in a sample of wound fluid. The preferred cell surface receptors are Intercellular adhesion molecule-1 (ICAM 1) and Tumor Necrosis Factor Receptor-2 (TNF-RII). The present invention also provides devices (e.g. biosensors) for use in such methods, and methods and products for diagnosing and treating infected wounds.

The invention belongs to the field of pharmacy, and relates to the application of propargyl cysteine and analogues thereof in preparation of medicaments for preventing and treating diseases related to cardiovascular system inflammation. Through in-vitro cell experiments, the results show that the propargyl cysteine and the analogues thereof can inhibit the expression of the mRNA and the protein of tumor necrosis factor alpha, interleukin-1beta and monocyte chemoattractant protein-1, increase the content of hydrogen sulfide in myocardial inflammation tissues, inhibit the expression of the mRNA of inducible nitric oxide synthase, cyclooxygenase-2 and intercellular adhesion molecule-1 related to the myocardial cells expressed inflammation, inhibit the activation of pathways ERK1/2 and NF-kB related to the inflammation in the myocardial cells, activate protein kinase B (Akt), and inhibit the production of oxygen free radicals in the myocardial cells, and can be prepared into the treatment medicaments for treating the diseases, such as ischemic heart disease, atherosis or myocardial infarction, related to the cardiovascular system inflammation.

The invention discloses a detection kit and a preparation method thereof, specifically elates to a kit for detecting premature rupture of membrane and a preparation method thereof. The kit comprises a multi-cell plate and reagents, wherein the reagents comprise: A, a magnetic microsphere suspension, wherein the magnetic microspheres are prepared by co-cross-linking hydroxylation magnetic microspheres with a diameter of 0.5-2 mum, N-hydroxysulfo succinic acid amide and carbodiimide, and a concentration of the magnetic microspheres in the suspension is 75-85/muL; B, phycoerythrin-labeled streptavidin and a biotin-labeled antibody detection solution, wherein the biotin is N-hydroxy succinic acid imino ester, the antibody is mouse anti-human soluble intercellular adhesion molecule-1 monoclonal antibody, and a concentration of the biotin-labeled antibody is 1.7-2 mg/mL; and C, a soluble intercellular adhesion molecule-1 protein standard substance and a standard substance dilution solution. The kit provides significantly increased sensitivity and specificity for the detection result of premature rupture of membrane so as to reduce diagnostic error incidence rate, wherein the sensitivity and the specificity can respectively achieve more than 99% and 98%.

The invention relates to the technical field of beauty treatment, and particularly relates to a human stem cell biobeauty raw material and a preparation method thereof. The biobeauty raw material is prepared from the following components in parts by weight: 30-50 parts of epidermal growth factor (EGF), 15-25 parts of basic fibroblast growth factor (bFGF), 10-15 parts of stem cell growth factor (SFC), 5-7.5 parts of intercellular adhesion molecule-1 (ICAM-1), 5-7.5 parts of insulin-like growth factor-1 (IGF-1), 10-15 parts of vascular endothelial growth factor (VEGF), 80-120 parts of human placental tissue fluid and 900-1200 parts of solvent. Under the synergistic action of the multiple cell growth factors, the biobeauty raw material can more efficiently improve the beauty treatment effect and delay senility; the cell growth factors adopt a human cell culture manner, thereby effectively guaranteeing the acceptance thereof by a human body and avoiding repulsion; and the human placental tissue fluid is added to ensure the activities of the biological factors at the same time of further improving the beauty treatment effect. The product preparation method is simple and easy to operate.

The invention provides a new application of syringin in medical science, in particular to application of syringin in the preparation of a medicine for treating acute gout. Syringin is extracted and separated from acanthopanax roots and other plants, and the extraction method comprises the following steps of: refluxing and extracting dry acanthopanax root powder with ethanol, recovering the ethanol, adding water to the concentrated solution, stirring to obtain a mixed suspension, extracting with petroleum ether, extracting the water layer with acetic ether, merging the acetic ether layer, concentrating under reduced pressure to obtain an extract, separating by using a silica gel column, carrying out gradient elution by using chloroform and methanol in sequence to obtain a coarse crystal, and recrystallizing with methanol to obtain a syringin crystal. Experimental researches show that syringin can protect an acute gout model due to human vascuoar endothelial cell damages caused by urate and inhibit the expression of ICAM-1 (Intercellular Adhesion Molecule-1); thus, syringin can be used for preparing a medicine for treating acute gout.

The invention relates to a gold label kit using NCAM-1 (neural cell adhesion molecule-1) as a detection index, which aims at obtaining a kit for detecting activeness of lupus nephritis. The gold label kit comprises a substrate, a water absorbing pad, a nitrocellulose membrane, a gold label pad and a sample pad, wherein the sample pad, the gold label pad, the nitrocellulose membrane and the water absorbing pad are sequentially connected to and cover the substrate; one part of the gold label pad is covered by the sample pad; a detection line coated by any of mouse-anti-human/rabbit-anti-human NCAM-1 monoclonal antibody or rabbit-anti-human/sheep-anti-human NCAM-1 polyclonal antibody, and a detection line coated by any of sheep-anti-mouse immune globulin G and sheep-anti-rabbit immune globulin G polyclonal antibodies are arranged on the nitrocellulose membrane; the gold label pad is coated by a complex which is formed by coupling of any of colloidal gold and mouse-anti-human/rabbit-anti-human NCAM-1 monoclonal antibody. The kit is used for detecting the NCAM-1 concentration in a urea sample, so as to judge the activeness of lupus nephritis, thereby realizing quick and non-wound detection.

The invention discloses a preparation method of an immunochromatographic test strip, and specifically relates to a preparation method of an immunochromatographic test strip for detecting premature rupture of membrane. the preparation of an immunochromatographic membrane in the preparation method is characterized in that a goat anti-human soluble intercellular adhesion molecule-1 polyclonal antibody is taken as a working solution of a detection line, and a goat anti-mouse IgG polyclonal antibody is taken as a working solution of a mass control line; the concentration of the working solution of the detection line is 1.5-2.5 mg/mL, and the concentration of the working solution of the mass control line is 0.5-1.5 mg/mL; and a nitrocellulose membrane is coated with the working solution of the detection line and the working solution of the mass control line, and then is dried at 36-38 DEG C for 8-12 hours to get the immunochromatographic membrane. The sensitivity and the specificity of the immunochromatographic test strip for detecting the premature rupture of membrane are improved obviously to be more than 97% and more than 93% respectively, and thus the occurrence rate of error diagnosis is reduced.

The present invention relates to a method for detecting anti-inflammatory activity of herbal tea by use of expression level of ICAM-1 (intercellular adhesion molecule-1) protein in human microvascularendothelial cells. The ICAM-1 protein on the surface of the HMEC-1 cells is directly labeled with a fluorescent antibody without extracting of RNA, the expression level of the ICAM-1 is detected by aflow cytometry, specifically, the HMEC-1 cells are inoculated in a cell culture plate, after the cells grow to form a single layer, the cell culture plate is incubated with a herbal tea test solutionand the cells, then the HMEC-1 cells are treated with LPS to induce inflammation, the expression level of the ICAM-1 on the surface of the inflammatory HMEC-1 cells is significantly increased, and after the cells are incubated with the herbal tea test solution, the expression level of the ICAM-1 is suppressed. The ICAM-1 protein on the surface of the HMEC-1 cells is labeled with the fluorescencelabeling ICAM-1 antibody, the expression level of the ICAM-1 on the surface of the inflammatory HMEC-1 cells incubated with the herbal tea test solution is quantitatively detected by the flow cytometry, and the expression level of the ICAM-1 protein is used as an index for measuring of the anti-inflammatory effect of the herbal tea test solution.

Pemphigus vulgaris (PV) is an autoimmune disease with a possible fatality of the skin and mucosae which is induced by an antibody against desmoglein 3 (Dsg3). Persistent production of anti-Dsg3 IgG can be induced by adoptively transferring spleen cells of a DSG3−/− mouse immunized with rDsg3 into an RAG2−/− immunodeficient mouse expressing Dsg3 protein. This IgG in the blood binds to the Dsg3 protein in vivo, induces the breakage of intercellular adhesion of keratinocytes and thus brings about the phenotype of pemphigus vulgaris involving the formation of blisters in the oral mucosa and the disappearance of resting hair. These effects are sustained over 6 months. By using this method, active disease model animals relating to various autoimmune diseases can be constructed.